{"id":61467,"date":"2025-06-23T01:03:43","date_gmt":"2025-06-22T23:03:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-data-show-delve-bios-metagenomic-testing-delivers-broader-deeper-pathogen-identification-compared-to-traditional-testing\/"},"modified":"2025-06-23T01:03:43","modified_gmt":"2025-06-22T23:03:43","slug":"new-data-show-delve-bios-metagenomic-testing-delivers-broader-deeper-pathogen-identification-compared-to-traditional-testing","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-data-show-delve-bios-metagenomic-testing-delivers-broader-deeper-pathogen-identification-compared-to-traditional-testing\/","title":{"rendered":"New Data Show Delve Bio\u2019s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing"},"content":{"rendered":"
\n

\nData Presented at the 2025 American Society for Microbiology Microbe Conference<\/i><\/p>\n

BOSTON–(BUSINESS WIRE)–#biotech<\/a>—Delve Bio<\/a>, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAmong the data presented at the meeting is a comparison of Delve\u2019s metagenomic cerebrospinal fluid (CSF) test, Delve Detect<\/a> CSF, compared to a traditional PCR-based meningitis\/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner.<\/p>\n

\n\u201cThis study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient\u2019s infection if mNGS were not included in the diagnostic workup,\u201d said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. \u201cThis study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections.\u201d<\/p>\n

\nThe study included 122 samples \u2014 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS.<\/p>\n

\nThe company\u2019s full presence at ASM Microbe 2025 includes:<\/p>\n